{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:05:01Z","timestamp":1792062301825,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T00:00:00Z","timestamp":1535328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.clml.2018.08.009","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T12:50:17Z","timestamp":1535547017000},"page":"788-795.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States"],"prefix":"10.1016","volume":"18","author":[{"given":"Michael R.","family":"Grunwald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady L.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph V.","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6162-1992","authenticated-orcid":false,"given":"Dilan","family":"Paranagama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreekant","family":"Parasuraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philomena","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.08.009_bib1","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.009_bib2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.08.009_bib3","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.009_bib4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.08.009_bib5","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A\u00a0prospective study of 338 patients with polycythemia vera: the impact of JAK2(V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.08.009_bib6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.22063","article-title":"The JAK2 exon 12 mutations: a comprehensive review","volume":"86","author":"Scott","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.08.009_bib7","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.009_bib8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1179\/102453310X12719010991740","article-title":"Treatment related changes in antifibrinolytic activity in patients with polycythemia vera","volume":"15","author":"Sonmez","year":"2010","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2018.08.009_bib9","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.009_bib10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2018.08.009_bib11","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.009_bib12","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.009_bib13","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.009_bib14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3109\/10428194.2011.619608","article-title":"Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms","volume":"53","author":"Johansson","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.08.009_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","article-title":"Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey","volume":"16","author":"Mesa","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2018.08.009_bib16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.009_bib17","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.3109\/10428194.2013.766732","article-title":"Patients with polycythemia vera have the worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms","volume":"54","author":"Abelsson","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.08.009_bib18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20 years","volume":"123","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2018.08.009_bib19","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","article-title":"Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study","volume":"33","author":"Hultcrantz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.009_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2018.08.009_bib21","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.08.009_bib22","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders","volume":"95","author":"Stein","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.08.009_bib23","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3109\/10428194.2012.759656","article-title":"Age-related differences in disease characteristics and clinical outcomes in polycythemia vera","volume":"54","author":"Stein","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2018.08.009_bib24","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.clml.2018.05.020","article-title":"Patient-reported outcomes data from REVEAL at the time of enrollment (baseline): a prospective observational study of patients with polycythemia vera in the United States","volume":"18","author":"Mesa","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2018.08.009_bib25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.clml.2018.08.009_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.08.009_bib27","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.009_bib28","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.amjmed.2013.04.016","article-title":"Commonly used data-collection approaches in clinical research","volume":"126","author":"Saczynski","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2018.08.009_bib30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.009_bib31","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018305937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018305937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:06Z","timestamp":1761870666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018305937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S2152265018305937"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.08.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}